---

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

---

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) July 16, 2004

 

---

 

AEOLUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

formerly Incara Pharmaceuticals Corporation

 

Delaware

(State or other jurisdiction of incorporation)

 

0-50481		56-1953785
(Commission File Number)		(IRS Employer ID Number)

 

P.O. Box 14287

79 T. W. Alexander Drive

4401 Research Commons, Suite 200

Research Triangle Park, North Carolina 27709

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code (919) 558-8688

 

---

---

Item 5. Other Events and Regulation FD Disclosure

 

On July 16, 2004, Incara Pharmaceuticals Corporation changed its name to Aeolus Pharmaceuticals, Inc. As a result its stock symbol changed to “AOLS”.

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: July 20, 2004		AEOLUS PHARMACEUTICALS, INC.     /s/ Richard W. Reichow Richard W. Reichow Executive Vice President and Chief Financial Officer